Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted,...
Pharmaceutical
Panbela Schedules Conference Call on, November 10, 2022, to Report 2022 Third Quarter Financial Results
MINNEAPOLIS, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination
SEC declared Effectiveness of Vickers’s registration statement on Form S-4Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve...
New Analyses of Sotagliflozin From the SOLOIST-WHF and SCORED Trials in High Cardiovascular Risk Patients to be Presented at the American Heart Association Scientific Sessions 2022
Featured oral presentation on the effect of sotagliflozin on cardiovascular mortality and hospital readmission rates for heart failure at 30-...
Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG
Sets company up to realize full commercial potential in fast growing U.S. marketSupports mutually beneficial interests between Biofrontera Inc and...
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
GMP Site Designed to Enable Potential Clinical and Commercial Production of AlloCAR T™ Products for Patients in Greater China, Taiwan,...
Mersana Therapeutics to Host Third Quarter 2022 Conference Call on November 7, 2022
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering...
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism
- PDUFA target action date is April 30, 2023 - MAA submission to EMA on track for this quarter COPENHAGEN,...
Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
- Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 -...
Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke
Sovateltide produced statistically significant and clinically meaningful improvements in neurological outcomes in acute cerebral ischemic stroke patients and was well...
IO Biotech to Participate in the Jefferies London Healthcare Conference
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022
NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset...
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
ARCA biopharma Announces Third Quarter 2022 Financial Results
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic optionsWESTMINSTER,...
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
NHF Seeking Donations Throughout November for Operation Brainstorm To Help Military Members and Veterans With Headache and Migraine Concerns
‘Every Day in November Will Be Dedicated to Giving’ – Tom Dabertin, CEO of NHF Service Dog The NHF supports...
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Media Release COPENHAGEN, Denmark; October 28, 2022 Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration...
Correction: Software Effective Solutions Subsidiary MEDCANA (OTC: SFWJ) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics with Colombia Partner Firms
MedCana's initial focus is on partnering and developing companies in Latin America with an initial focus in Colombia and partnerships...
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Outlook...